Spots Global Cancer Trial Database for masitinib
Every month we try and update this database with for masitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | NCT00812240 | Gastrointestina... | Masitinib Imatinib | 18 Years - | AB Science | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | NCT01470131 | Multiple Myelom... | Masitinib Placebo Bortezomib Dexamethasone | 18 Years - | AB Science | |
| Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | NCT01266369 | Mastocytosis | masitinib | 18 Years - | AB Science | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | NCT00789633 | Pancreatic Canc... | Masitinib Placebo Gemcitabine | 18 Years - | AB Science | |
| Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer | NCT03556956 | Colorectal Canc... | Masitinib | 18 Years - | AB Science | |
| Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | NCT02490488 | Ovarian Cancer | Masitinib Gemcitabine Placebo | 18 Years - | AB Science | |
| Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis | NCT01433497 | Multiple Sclero... Multiple Sclero... Multiple Sclero... | Masitinib Placebo | 18 Years - 75 Years | AB Science | |
| Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | NCT00812240 | Gastrointestina... | Masitinib Imatinib | 18 Years - | AB Science | |
| Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | NCT01694277 | Gastrointestina... | Masitinib Sunitinib | 18 Years - | AB Science | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | NCT04333108 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science | |
| Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | NCT01280565 | Metastatic Mela... | Masitinib Dacarbazine | 18 Years - | AB Science | |
| Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | NCT00789633 | Pancreatic Canc... | Masitinib Placebo Gemcitabine | 18 Years - | AB Science | |
| Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT03761225 | Metastatic Cast... | Masitinib Docetaxel Prednisone Placebo | 18 Years - | AB Science | |
| Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT03761225 | Metastatic Cast... | Masitinib Docetaxel Prednisone Placebo | 18 Years - | AB Science | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis | NCT00814073 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
